This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Cell & Gene Therapy Manufacturing & Commercialization US
September 27-30, 2022
Boston Convention and Exhibition CenterBoston, MA

Kevin Healy
Senior Vice President, Regulatory Affairs, Pharmacovigilance, and Quality at Enzyvant


Kevin Healy, PhD, RAC

Kevin Healy is Enzyvant’s Senior Vice President, Regulatory Affairs, Pharmacovigilance, and Quality. In this role, Kevin had primary responsibility for guiding RETHYMIC®, designated as a Regenerative Medicine Advanced Therapy (RMAT), to an FDA approval in 2021. Kevin has over 15 years of biotech and pharmaceutical experience, and has been instrumental in advancing the development and approval of multiple therapies at Gilead Sciences, Mallinckrodt Pharmaceuticals, and Roivant Sciences.


Kevin received his BS in Biological Sciences from Cornell University, his PhD in Biochemistry from the University of Wisconsin–Madison, and completed a postdoctoral research fellowship at the University of North Carolina at Chapel Hill.

Agenda Sessions

  • Obtaining Commercial Approval for a Tissue Based Regenerative Medicine Product